Reimbursed Care Access in Iceland

Currently classified as a strictly controlled substance under Iceland's Narcotics Act (listed by name in the statutory controlled-substances list), with no authorised medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under Iceland's Narcotics Act, with no authorised medical use outside of approved clinical research. #

Esketamine (marketed as SPRAVATO) is authorised at the European level for treatment‑resistant major depressive disorder, and that EU authorisation is the primary regulatory basis for access in EEA/EEA‑associated states, including Iceland. The European Medicines Agency product page documents the marketing authorisation and the clinical indication (adults with treatment‑resistant major depressive disorder, used in combination with an oral antidepressant). #.

Icelandic reimbursement and public‑sector coverage for any new medicine are determined through processes managed by the Icelandic Medicines Agency (Lyfjastofnun Íslands / IMA) and national pricing/reimbursement rules; decisions on whether a centrally authorised product is placed on Iceland's reimbursement lists and funded by public payers depend on submission and evaluation under Icelandic pricing & reimbursement procedures. For general information on the mechanism that governs medicine pricing and reimbursement decisions in Iceland, see the Icelandic Medicines Agency guidance on Pricing and Reimbursement. #.

Practical implications in Iceland: because Spravato is EMA‑authorised, it can be placed on the Icelandic market subject to national authorisation/notification procedures, and could be prescribed in appropriate specialist settings (psychiatry) under the EU/EEA regulatory framework. However, public reimbursement is not automatic — reimbursement requires an Icelandic pricing/reimbursement decision and is commonly subject to indication-specific criteria and possible restrictions (e.g., specialist prescribing, administration under supervised conditions). At present there is no publicly‑available Icelandic government source indicating universal public reimbursement specifically for Spravato; clinicians and health administrators must therefore check Icelandic Medicines Agency decisions and national reimbursement listings for current coverage status. # #.

Ketamine is an established, licensed anaesthetic and analgesic agent used within conventional medicine and is included on the WHO Model List of Essential Medicines for anaesthesia, supporting routine medical availability for surgical and emergency uses. #.

In the Icelandic context, ketamine is available as a licensed anaesthetic within hospitals and other authorised medical settings (i.e., routine anaesthesia/analgesia uses). Regarding psychiatric use, ketamine (intravenous or intranasal racemic formulations) is widely used internationally as an off‑label treatment for severe or treatment‑resistant depression in specialized clinics; in Iceland the clinical and policy discourse around ketamine and other psychedelic treatments is active but largely focused on research, specialist practice, and private‑sector provision rather than broad public reimbursement. Local professional discussion and reporting note increasing interest in psychedelic approaches (including ketamine) and calls for structured research under healthcare oversight. # #.

Reimbursement and access nuance: ketamine’s conventional uses (anaesthesia, analgesia) are delivered within hospital budgets or standard drug procurement and are normally covered as part of hospital care; off‑label use for depression would typically be arranged outside standard mental‑health medicine reimbursement unless explicitly approved or contracted by payers, meaning many off‑label ketamine infusions for depression are delivered in private settings or via research protocols unless/until specific public reimbursement rules are adopted.

Currently classified as a strictly controlled substance under Iceland's Narcotics Act (DMT is listed by name in the statutory controlled‑substances list), with no authorised medical use outside of approved clinical research. #

Icelandic narcotics law explicitly controls DMT by name; 5‑MeO‑DMT is a structural/pharmacological analogue of DMT and in practice is treated under the same prohibitions and/or analogue provisions — there is no authorised medical use outside approved clinical research in Iceland. Standard legal position: controlled under the Narcotics Act, with access only via approved clinical trials or ministerial exemptions where explicitly granted. #

Currently classified as a strictly controlled substance under Iceland's narcotics scheduling framework (ibogaine is specifically named in Icelandic lists of controlled substances) and has no authorised medical use in routine care; access is limited to approved clinical research only. #

Ayahuasca as a preparation contains DMT (and is thus captured by the statutory control of DMT); it is therefore treated as a controlled substance under Icelandic law with no authorised medical use outside approved clinical research. Personal use or religious exemptions are not established pathways to legal medical access in Iceland; any lawful use would require explicit research or ministerial exemption. #

Specifically listed as a controlled substance in Icelandic law (mescaline is named in the statutory list), and therefore has no authorised medical use in routine care in Iceland outside of approved clinical research or narrow exemptions. #

Members of the 2C family and similar substituted phenethylamines (commonly referenced as '2C‑X' class compounds) are captured by Iceland’s broad narcotics controls either by specific listing or by analogue/structural‑class provisions; there is no authorised medical use and access is limited to approved research only. #